Altered peptide ligands can modify the Th2 T cell response to the immunodominant 161-175 peptide of LACK (Leishmania homolog for the receptor of activated C kinase)

Molecular Immunology

Volumn 46, Issue 3, 2009, Pages 366-374

  Jensen, Kirk D C ^a   Sercarz, Eli E ^a   Gabaglia, Claudia Raja ^a  

^a TORREY PINES INSTITUTE FOR MOLECULAR STUDIES   (United States)

Author keywords

Agonists; Altered peptide ligands; Core determinant; Flanking residues; I Ad; LACK; Leishmania; T cell receptor; Th1 Th2

Indexed keywords

ALTERED PEPTIDE LIGAND; CELL PROTEIN; GAMMA INTERFERON; INTERLEUKIN 4; LACK 161-175 PEPTIDE; PEPTIDE VACCINE; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RELEASE; DNA FLANKING REGION; IMMUNIZATION; IMMUNOMODULATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL; TRANSGENIC MOUSE;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMALS; ANTIGENS, PROTOZOAN; CELL LINE; CELL PROLIFERATION; CROSS-PRIMING; CYTOKINES; IMMUNIZATION; IMMUNODOMINANT EPITOPES; INTERFERON-GAMMA; INTERLEUKIN-4; LEISHMANIA MAJOR; LIGANDS; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; PEPTIDES; PROTOZOAN PROTEINS; PROTOZOAN VACCINES; RECEPTORS, ANTIGEN, T-CELL; TH2 CELLS;

LEISHMANIA MAJOR; MUS; MUS MUSCULUS;

EID: 57749104693     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2008.10.024     Document Type: Article

References (41)

1. Anderson R.P., van Heel D.A., Tye-Din J.A., Jewell D.P., and Hill A.V. Antagonists and non-toxic variants of the dominant wheat gliadin T cell epitope in coeliac disease. Gut 55 (2006) 485-491
2. Arnold P.Y., La Gruta N.L., Miller T., Vignali K.M., Adams P.S., Woodland D.L., and Vignali D.A. The majority of immunogenic epitopes generate CD4+ T cells that are dependent on MHC class II-bound peptide-flanking residues. J. Immunol. 169 (2002) 739-749
3. Borbulevych O.Y., Baxter T.K., Yu Z., Restifo N.P., and Baker B.M. Increased immunogenicity of an anchor-modified tumor-associated antigen is due to the enhanced stability of the peptide/MHC complex: implications for vaccine design. J. Immunol. 174 (2005) 4812-4820
4. Carson R.T., Vignali K.M., Woodland D.L., and Vignali D.A. T cell receptor recognition of MHC class II-bound peptide flanking residues enhances immunogenicity and results in altered TCR V region usage. Immunity 7 (1997) 387-399
5. Dai S., Huseby E.S., Rubtsova K., Scott-Browne J., Crawford F., Macdonald W.A., Marrack P., and Kappler J.W. Crossreactive T Cells spotlight the germline rules for alphabeta T cell-receptor interactions with MHC molecules. Immunity 28 (2008) 324-334
6. Douat-Casassus C., Marchand-Geneste N., Diez E., Gervois N., Jotereau F., and Quideau S. Synthetic anticancer vaccine candidates: rational design of antigenic peptide mimetics that activate tumor-specific T-cells. J. Med. Chem. 50 (2007) 1598-1609
7. England R.D., Kullberg M.C., Cornette J.L., and Berzofsky J.A. Molecular analysis of a heteroclitic T cell response to the immunodominant epitope of sperm whale myoglobin. Implications for peptide partial agonists. J. Immunol. 155 (1995) 4295-4306
8. Feinerman O., Germain R.N., and Altan-Bonnet G. Quantitative challenges in understanding ligand discrimination by alphabeta T cells. Mol. Immunol. 45 (2008) 619-631
9. Gabaglia C.R., Pedersen B., Hitt M., Burdin N., Sercarz E.E., Graham F.L., Gauldie J., and Braciak T.A. A single intramuscular injection with an adenovirus-expressing IL-12 protects BALB/c mice against Leishmania major infection, while treatment with an IL-4-expressing vector increases disease susceptibility in B10.D2 mice. J. Immunol. 162 (1999) 753-760
10. Hennecke J., Carfi A., and Wiley D.C. Structure of a covalently stabilized complex of a human alphabeta T-cell receptor, influenza HA peptide and MHC class II molecule, HLA-DR1. Embo J. 19 (2000) 5611-5624
11. Holscher C., Arendse B., Schwegmann A., Myburgh E., and Brombacher F. Impairment of alternative macrophage activation delays cutaneous leishmaniasis in nonhealing BALB/c mice. J. Immunol. 176 (2006) 1115-1121
12. Hunt D.F., Michel H., Dickinson T.A., Shabanowitz J., Cox A.L., Sakaguchi K., Appella E., Grey H.M., and Sette A. Peptides presented to the immune system by the murine class II major histocompatibility complex molecule I-Ad. Science 256 (1992) 1817-1820
13. Huseby E.S., White J., Crawford F., Vass T., Becker D., Pinilla C., Marrack P., and Kappler J.W. How the T cell repertoire becomes peptide and MHC specific. Cell 122 (2005) 247-260
14. Julia V., Rassoulzadegan M., and Glaichenhaus N. Resistance to Leishmania major induced by tolerance to a single antigen. Science 274 (1996) 421-423
15. Kelly B.L., and Locksley R.M. The Leishmania major LACK antigen with an immunodominant epitope at amino acids 156-173 is not required for early Th2 development in BALB/c mice. Infect. Immun. 72 (2004) 6924-6931
16. Kinnunen T., Jutila K., Kwok W.W., Rytkonen-Nissinen M., Immonen A., Saarelainen S., Narvanen A., Taivainen A., and Virtanen T. Potential of an altered peptide ligand of lipocalin allergen Bos d 2 for peptide immunotherapy. J. Allergy Clin. Immunol. 119 (2007) 965-972
17. Kumar V., Bhardwaj V., Soares L., Alexander J., Sette A., and Sercarz E. Major histocompatibility complex binding affinity of an antigenic determinant is crucial for the differential secretion of interleukin 4/5 or interferon gamma by T cells. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 9510-9514
18. Malherbe L., Filippi C., Julia V., Foucras G., Moro M., Appel H., Wucherpfennig K., Guery J.C., and Glaichenhaus N. Selective activation and expansion of high-affinity CD4+ T cells in resistant mice upon infection with Leishmania major. Immunity 13 (2000) 771-782
19. Malherbe L., Hausl C., Teyton L., and McHeyzer-Williams M.G. Clonal selection of helper T cells is determined by an affinity threshold with no further skewing of TCR binding properties. Immunity 21 (2004) 669-679
20. Moudgil K.D., Sercarz E.E., and Grewal I.S. Modulation of the immunogenicity of antigenic determinants by their flanking residues. Immunol. Today 19 (1998) 217-220
21. Mougneau E., Altare F., Wakil A.E., Zheng S., Coppola T., Wang Z.E., Waldmann R., Locksley R.M., and Glaichenhaus N. Expression cloning of a protective Leishmania antigen. Science 268 (1995) 563-566
22. Murray J.S. How the MHC selects Th1/Th2 immunity. Immunol. Today 19 (1998) 157-163
23. Murray J.S., Ferrandis-Edwards D., Wolfe C.J., and Schountz T. Major histocompatibility complex regulation of T helper functions mapped to a peptide C terminus that controls ligand density. Eur. J. Immunol. 24 (1994) 2337-2344
24. Myers L.K., Tang B., Rosioniec E.F., Stuart J.M., and Kang A.H. An altered peptide ligand of type II collagen suppresses autoimmune arthritis. Crit. Rev. Immunol. 27 (2007) 345-356
25. Nelson C.A., Roof R.W., McCourt D.W., and Unanue E.R. Identification of the naturally processed form of hen egg white lysozyme bound to the murine major histocompatibility complex class II molecule I-Ak. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 7380-7383
26. Pfeiffer C., Stein J., Southwood S., Ketelaar H., Sette A., and Bottomly K. Altered peptide ligands can control CD4 T lymphocyte differentiation in vivo. J. Exp. Med. 181 (1995) 1569-1574
27. Pingel S., Launois P., Fowell D.J., Turck C.W., Southwood S., Sette A., Glaichenhaus N., Louis J.A., and Locksley R.M. Altered ligands reveal limited plasticity in the T cell response to a pathogenic epitope. J. Exp. Med. 189 (1999) 1111-1120
28. Reay P.A., Kantor R.M., and Davis M.M. Use of global amino acid replacements to define the requirements for MHC binding and T cell recognition of moth cytochrome c (93-103). J. Immunol. 152 (1994) 3946-3957
29. Reiner S.L., Wang Z.E., Hatam F., Scott P., and Locksley R.M. TH1 and TH2 cell antigen receptors in experimental leishmaniasis. Science 259 (1993) 1457-1460
30. Reinherz E.L., Tan K., Tang L., Kern P., Liu J., Xiong Y., Hussey R.E., Smolyar A., Hare B., Zhang R., Joachimiak A., Chang H.C., Wagner G., and Wang J. The crystal structure of a T cell receptor in complex with peptide and MHC class II. Science 286 (1999) 1913-1921
31. Rudolph M.G., Stanfield R.L., and Wilson I.A. How TCRs bind MHCs, peptides, and coreceptors. Annu. Rev. Immunol. 24 (2006) 419-466
32. Sacks D., and Noben-Trauth N. The immunology of susceptibility and resistance to Leishmania major in mice. Nat. Rev. Immunol. 2 (2002) 845-858
33. Sant'Angelo D.B., Waterbury G., Preston-Hurlburt P., Yoon S.T., Medzhitov R., Hong S.C., and Janeway Jr. C.A. The specificity and orientation of a TCR to its peptide-MHC class II ligands. Immunity 4 (1996) 367-376
34. Schountz T., Kasselman J.P., Martinson F.A., Brown L., and Murray J.S. MHC genotype controls the capacity of ligand density to switch T helper (Th)-1/Th-2 priming in vivo. J. Immunol. 157 (1996) 3893-3901
35. Scott C.A., Peterson P.A., Teyton L., and Wilson I.A. Crystal structures of two I-Ad-peptide complexes reveal that high affinity can be achieved without large anchor residues. Immunity 8 (1998) 319-329
36. Sercarz E.E., and Maverakis E. MHC-guided processing: binding of large antigen fragments. Nat. Rev. Immunol. 3 (2003) 621-629
37. Sette A., Buus S., Colon S., Smith J.A., Miles C., and Grey H.M. Structural characteristics of an antigen required for its interaction with Ia and recognition by T cells. Nature 328 (1987) 395-399
38. Sette A., Buus S., Colon S., Miles C., and Grey H.M. I-Ad-binding peptides derived from unrelated protein antigens share a common structural motif. J. Immunol. 141 (1988) 45-48
39. Sette A., Adorini L., Appella E., Colon S.M., Miles C., Tanaka S., Ehrhardt C., Doria G., Nagy Z.A., Buus S., et al. Structural requirements for the interaction between peptide antigens and I-Ed molecules. J. Immunol. 143 (1989) 3289-3294
40. Tang Y., Lin Z., Ni B., Wei J., Han J., Wang H., and Wu Y. An altered peptide ligand for naive cytotoxic T lymphocyte epitope of TRP-2(180-188) enhanced immunogenicity. Cancer Immunol. Immunother. 56 (2007) 319-329
41. Wucherpfennig K.W., Allen P.M., Celada F., Cohen I.R., De Boer R., Garcia K.C., Goldstein B., Greenspan R., Hafler D., Hodgkin P., Huseby E.S., Krakauer D.C., Nemazee D., Perelson A.S., Pinilla C., Strong R.K., and Sercarz E.E. Polyspecificity of T cell and B cell receptor recognition. Semin. Immunol. 19 (2007) 216-224